FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4288032946> ?p ?o ?g. }

• W4288032946 endingPage "e543" @default.
• W4288032946 startingPage "e534" @default.
• W4288032946 abstract "Late initiation of antiretrovirals in pregnancy is associated with increased risk of perinatal transmission and higher infant mortality. We report the final 72-week postpartum results for efficacy and safety of dolutegravir-based compared with efavirenz-based regimens in mothers and infants.DolPHIN-2 was a randomised, open-label trial. Pregnant women in South Africa and Uganda aged at least 18 years, with untreated but confirmed HIV infection and an estimated gestation of at least 28 weeks, initiating antiretroviral therapy in third trimester were eligible for inclusion. Eligible women were randomly assigned (1:1) to receive either dolutegravir-based (50 mg dolutegravir, 300 mg tenofovir disoproxil fumarate, and either 200 mg emtricitabine in South Africa or 300 mg lamivudine in Uganda) or efavirenz-based (fixed dose combination 600 mg tenofovir disoproxil fumarate plus either emtricitabine in South Africa or lamivudine in Uganda) therapy. The primary efficacy outcome was the time to a viral load of less than 50 copies per mL measured at 6, 12, 24, 48, and 72 weeks postpartum with a Cox model adjusting for viral load and CD4 cell count. Safety endpoints were summarised by the number of women and infants with events. This trial is registered with ClinicalTrials.gov, NCT03249181.Between Jan 23 and Aug 15, 2018, 280 women were screened for inclusion, of whom 268 (96%) women were randomly assigned: 133 (50%) to the efavirenz group and 135 (50%) to the dolutegravir group. 250 (93%; 125 [50%] in the efavirenz group and 125 [50%] in the dolutegravir group) women were included in the intention-to-treat analysis of efficacy. Median time to viral load of less than 50 copies per mL was 4·1 weeks (IQR 4·0-5·1) in the dolutegravir group compared with 12·1 weeks (10·7-13·3) in the efavirenz group (adjusted hazard ratio [HR] 1·93 [95% CI 1·5-2·5]). At 72 weeks postpartum, 116 (93%) mothers in the dolutegravir group and 114 (91%) in the efavirenz group had a viral load of less than 50 copies per mL. Of 57 (21%) mothers with a severe adverse event, three (2%) in the dolutegravir group and five (4%) in the efavirenz group were related to the drug (dolutegravir drug-related events were one woman each with suicidal ideation, suicide attempt, herpes zoster meningitis; efavirenz drug-related events were one woman each with suicide attempt and liver cirrhosis, and three people with drug-induced liver injury). Of 136 (56%) infants in whom severe adverse events were recorded, none were related to the study drugs. In addition to the three infant HIV infections detected at birth in the dolutegravir group that have been previously reported, an additional transmission in the efavirenz group occurred during breastfeeding despite optimal maternal viral suppression and serial negative infant tests in the first year of life.Dolutegravir was safe and well tolerated, supporting updated WHO treatment recommendations in pregnant and breastfeeding women. Infant HIV transmissions can occur during breastfeeding despite persistently undetectable maternal viral load highlighting the need for continued infant testing.Unitaid." @default.
• W4288032946 created "2022-07-27" @default.
• W4288032946 creator A5000086630 @default.
• W4288032946 creator A5000472277 @default.
• W4288032946 creator A5001132722 @default.
• W4288032946 creator A5003775503 @default.
• W4288032946 creator A5004951116 @default.
• W4288032946 creator A5006067850 @default.
• W4288032946 creator A5007374146 @default.
• W4288032946 creator A5007876312 @default.
• W4288032946 creator A5010443306 @default.
• W4288032946 creator A5011745167 @default.
• W4288032946 creator A5012223514 @default.
• W4288032946 creator A5012289865 @default.
• W4288032946 creator A5014615776 @default.
• W4288032946 creator A5016652178 @default.
• W4288032946 creator A5021455287 @default.
• W4288032946 creator A5021568119 @default.
• W4288032946 creator A5024818901 @default.
• W4288032946 creator A5026480684 @default.
• W4288032946 creator A5027239695 @default.
• W4288032946 creator A5027581358 @default.
• W4288032946 creator A5029756580 @default.
• W4288032946 creator A5032374309 @default.
• W4288032946 creator A5032992537 @default.
• W4288032946 creator A5033299238 @default.
• W4288032946 creator A5033445078 @default.
• W4288032946 creator A5034557139 @default.
• W4288032946 creator A5035641829 @default.
• W4288032946 creator A5036837800 @default.
• W4288032946 creator A5037433490 @default.
• W4288032946 creator A5041150446 @default.
• W4288032946 creator A5041365930 @default.
• W4288032946 creator A5042034712 @default.
• W4288032946 creator A5042780925 @default.
• W4288032946 creator A5043239147 @default.
• W4288032946 creator A5044287061 @default.
• W4288032946 creator A5046774942 @default.
• W4288032946 creator A5048050447 @default.
• W4288032946 creator A5049011311 @default.
• W4288032946 creator A5049811678 @default.
• W4288032946 creator A5051110510 @default.
• W4288032946 creator A5051722143 @default.
• W4288032946 creator A5055903205 @default.
• W4288032946 creator A5056543579 @default.
• W4288032946 creator A5058343831 @default.
• W4288032946 creator A5063085944 @default.
• W4288032946 creator A5064842935 @default.
• W4288032946 creator A5065517027 @default.
• W4288032946 creator A5067021414 @default.
• W4288032946 creator A5068703662 @default.
• W4288032946 creator A5071101727 @default.
• W4288032946 creator A5072080872 @default.
• W4288032946 creator A5074224292 @default.
• W4288032946 creator A5076774936 @default.
• W4288032946 creator A5077934314 @default.
• W4288032946 creator A5080233718 @default.
• W4288032946 creator A5080667228 @default.
• W4288032946 creator A5080846431 @default.
• W4288032946 creator A5080869500 @default.
• W4288032946 creator A5081000707 @default.
• W4288032946 creator A5081855852 @default.
• W4288032946 creator A5082629122 @default.
• W4288032946 creator A5083035911 @default.
• W4288032946 creator A5083382107 @default.
• W4288032946 creator A5083949059 @default.
• W4288032946 creator A5084732324 @default.
• W4288032946 creator A5085396826 @default.
• W4288032946 creator A5087654540 @default.
• W4288032946 creator A5089793108 @default.
• W4288032946 date "2022-08-01" @default.
• W4288032946 modified "2023-10-07" @default.
• W4288032946 title "72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study" @default.
• W4288032946 cites W1985844709 @default.
• W4288032946 cites W1995422727 @default.
• W4288032946 cites W2094133941 @default.
• W4288032946 cites W2094241860 @default.
• W4288032946 cites W2130920604 @default.
• W4288032946 cites W2153189426 @default.
• W4288032946 cites W2155741047 @default.
• W4288032946 cites W2219927710 @default.
• W4288032946 cites W2225194404 @default.
• W4288032946 cites W2555080176 @default.
• W4288032946 cites W2737438099 @default.
• W4288032946 cites W2768806056 @default.
• W4288032946 cites W2810532599 @default.
• W4288032946 cites W2962964639 @default.
• W4288032946 cites W2995015948 @default.
• W4288032946 cites W3006965005 @default.
• W4288032946 cites W3021321833 @default.
• W4288032946 cites W3089405003 @default.
• W4288032946 cites W3090200844 @default.
• W4288032946 cites W3091551464 @default.
• W4288032946 cites W3119144888 @default.
• W4288032946 cites W3142355365 @default.
• W4288032946 doi "https://doi.org/10.1016/s2352-3018(22)00173-4" @default.
• W4288032946 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35905752" @default.
• W4288032946 hasPublicationYear "2022" @default.

• next